JY
VINC

Jeff Yass’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Jeff Yass’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,069
Closed -$5.62K – 13787
2024
Q4 		$5.62K Sell
1,069
-530
-33% -$3.48K ﹤0.01% 12003
2024
Q3 		$22.9K Buy
+1,599
New +$21.9K ﹤0.01% 11597
2023
Q2 		– Sell
-1,356
Closed -$28.2K – 13374
2023
Q1 		$28.2K Buy
+1,356
New +$30.4K ﹤0.01% 11937
2022
Q3 		– Sell
-878
Closed -$23K – 14312
2022
Q2 		$23K Buy
878
+223
+34% +$9.92K ﹤0.01% 12332
2022
Q1 		$52K Buy
+655
New +$80.9K ﹤0.01% 12298
2021
Q2 		– Sell
-543
Closed -$210K – 13404
2021
Q1 		$210K Buy
+543
New +$219K ﹤0.01% 11346

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's VINC Position: Q1 2025 in Review

Jeff Yass sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 1,069 shares — an estimated $5.62K sold.

Jeff Yass first reported a position in VINC in Q1 2021 and held it in 6 quarters. The position peaked at $210K in Q1 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

  • Jeff Yass reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Jeff Yass sold 1,069 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $5.62K.
  • Jeff Yass first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • Jeff Yass's Vincerx Pharma, Inc. Common Stock position peaked at $210K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.